Navigation Links
Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
Date:3/24/2008

SAN DIEGO, Calif., March 24 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of blood substitutes, today announced that it has completed enrollment in a Phase III trial of its lead product Hemospan(R).

The completed study of 460 patients is one of two parallel Phase III clinical trials being conducted at 36 academic medical centers in the United Kingdom, Sweden, the Netherlands, Belgium, Poland and the Czech Republic. The two randomized, placebo-controlled studies, which will enroll a combined total of more than 800 elective orthopedic surgery patients, are designed to evaluate the safety and efficacy of Hemospan in preventing and treating hemodynamic instability, especially hypotension, or low blood pressure, during surgery.

"We are pleased to have completed enrollment in this Phase III study," said Dr. Robert Winslow, Chairman, President and CEO of Sangart. "This represents a major milestone for Sangart as we continue to gather evidence of Hemospan's potential to satisfy the significant and growing demand for a safe and effective agent to improve oxygen transport in clinical settings where blood is often transfused."

Sangart also announced that enrollment in the second Phase III study is progressing well and is expected to be completed in the near future.

No similar oxygen transport agents are currently on the market in Europe or the United States. Earlier clinical studies indicate that Hemospan's novel oxygen delivery mechanism has the potential to provide a safe and effective alternative to blood transfusions.

About Sangart

Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as alternatives to blood transfusions.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
2. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
3. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
4. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
5. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
6. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
7. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
10. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
11. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced it received ... H, a hemp-based, advanced headache relief product, for planned ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Sept. 18 S*BIO Pte Ltd today announced the,initiation ... potent and,orally-active JAK2 inhibitor, in patients with leukemia and ... SB1518 comprise of ascending,dose studies conducted at several leading ... to enroll up to 60 patients and are,designed to ...
... Payments of $8.5 Million -, MONTVALE, N.J., ... ) today announced that it has amended,its nicotinic ... the,Phase 2 development program for R3487/MEM 3454 in ... currently,conducting a Phase 2 trial of R3487/MEM 3454 ...
Cached Medicine Technology:S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies 2Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program 2Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program 3Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program 4
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... will gather for the Experimental Biology 2008 meeting in ... of the annual meeting, now in its 18th year, ... research presentations and exhibits have been selected because of ... Scientists and clinicians from dozens of different disciplines, from ...
... Jim Reynolds, MD join executive team; Jerry Noyce announces ... ... HealthFitness (OTC,Bulletin Board: HFIT) announced today that John Griffin has ... the,company as chief medical officer and Jerry Noyce has retired as ...
... BEIJING, Feb. 4 /Xinhua-PRNewswire/ -- The Red Cross ... payment service provider in China, to,launch online donation ... make online donations for snow storm victims in ... http://www.yeepay.com/mlove ., (Logo: http://www.newscom.com/cgi-bin/prnh/20051211/CNM005 ...
... follows positive phase I data from novel product candidate ... the oral ... Amira Pharmaceuticals and,GlaxoSmithKline today announced they have entered ... FLAP,(5-Lipoxygenase Activating Protein ) inhibitors for the treatment of,respiratory ...
... more than 78% , , MONDAY, Feb. 4 (HealthDay News) -- ... a new study shows it may also ease the pain ... sugar-and-water solution will also ease parents, fears and boost immunization ... to get their children vaccinated," said study author Linda Hatfield, ...
... SAP Public Services, Inc.,a subsidiary of SAP ... Corbett as vice,president of its U.S. healthcare practice. ... sector and,government-driven initiatives to improve the quality and ... be responsible for growing,SAP,s business in the U.S. ...
Cached Medicine News:Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 2Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 3Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 4Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 5Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 6Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 2Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 3Health News:Red Cross Partners with YeePay on China Snow Disaster Relief 2Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 2Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 3Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 4Health News:Sugar Water Eases Pain of Infant Vaccinations 2Health News:Sugar Water Eases Pain of Infant Vaccinations 3Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 2Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 3Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 4Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 5
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Woodlyn Lensmeter is designed to be used in either a prescription laboratory setting or professional office. Its titable position angle offers personal comfort. The easily operated marking device pro...
Nidek Fundus Camera NM-200D's compact, lightweight body with user-friendly color touch screen display provides more options to treat more patients, and is more comfortable to use....
Medicine Products: